Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0NMCNN)
| ADC Name |
SGN-CD48A
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SGN-CD48A
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-SLAMF2 mAb
|
Antibody Info | ||||
| Antigen Name |
CD48 antigen (CD48)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
PEGylated β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Effective Concentration (EC50) |
1.00-11.00
|
ng/mL
|
Multiple myeloma cells
|
Multiple myeloma
|
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have MM requiring systemic treatment (per IMWG) refractory to prior PI, IMiD, and anti-CD38 antibody therapy, with measurable disease and adequate organ function (ECOG 0-1). Key exclusions: Grade 2+ neuropathy, recent malignancies (past 3 years), active CNS disease, uncontrolled infections (HIV/HBV/HCV), prior allogeneic transplant, recent cardiovascular events, or use of P-gp/CYP3A modulators within 14 days.
Click to Show/Hide
|
||||
| Administration Dosage |
Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03379584 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma | ||||
| Primary Endpoint |
Safety outcomes monitor adverse events (AEs) including severity, seriousness, and relatedness through 1 month after the last dose, along with laboratory abnormalities and dose-limiting toxicities (DLTs) within 3 weeks of first treatment.
|
||||
| Other Endpoint |
Efficacy measures include objective response rate (ORR; stringent CR/CR/VGPR/PR), CR rate, duration of response (DOR and CR duration up to ~3 years), PFS, OS, pharmacokinetics (blood concentrations of SGN-CD48A/metabolites), and incidence of antitherapeutic antibodies.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03379584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma. | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 75% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | EJM cells | CVCL_2030 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 87.50% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | U-266 cells | CVCL_0015 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.00-11.00 ng/mL | High CD48 expresion (CD48+++/++; 1260 MSLN molecules/cell) | ||
| Method Description |
Cytotoxic activity of SGN-CD48A was demonstrated in a panel of human MM cell lines in vitro.
|
||||
| In Vitro Model | Multiple myeloma | Multiple myeloma cells | Homo sapiens | ||
References